FeesSafety
Pluang+

Perpetua Resources secures $40M U.S. Army grant to explore tungsten at Idaho's Stibnite mine.

Market News
27 Oct 2026, 00:45 WIB
PRNewsWire
View Source
Bullish
Perpetua Resources secures $40M U.S. Army grant to explore tungsten at Idaho's Stibnite mine.

Perpetua Resources received a $40 million, 36-month grant from the U.S. Army to explore tungsten production at the historic Stibnite Mining District in Idaho. The funding supports drilling, metallurgical testing, and construction of an underground decline to access high-grade tungsten, gold, and antimony deposits. This project aims to reduce U.S. reliance on imported tungsten, a critical mineral for defense and manufacturing. Perpetua will match the Army's funding and plans to continue advancing exploration under the Hangar Flats pit, which holds significant gold and antimony resources beyond current reserves.

Perpetua Resources' funding for tungsten supply is the subject, with Pluang's Basic Materials sector data providing market context as of Oct 27, 2026 04:11 WIB. Of 83 priced US stocks in this sector, 43 rose and 39 fell. Notable movers include Corteva Inc. (CTVA) at USD 11.93 with a -4.22% change and 100% buy orders, Vale SA (VALE) at USD 11.92 with a -3.87% change and 94% buy orders, and Cleveland-Cliffs Inc. (CLF) at USD 13.39 with a -3.67% change and 100% sell orders. The most notable figure is Corteva's 100% buy order activity on Pluang.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App